HDAC9 and breast carcinoma: Furthermore, either MGDAs co-culture or treatment of β-hydroxybutyrate, an intrinsic histone deacetylase (HDAC) inhibitor, increases histone H3K9 acetylation and induces expressions of IL-1β and LCN2 to enhance tumorigenicity in MCT2-expressing breast cancer cells.